Get caught up quickly on the top news and calls moving stocks with these Top Fives, as compiled by the editors of The Fly. 

1. STOCK NEWS: 

• Thermo Fisher (TMO) reiterated FY21 guidance and provided a better than expected view on FY22 [more]
• Diamondback Energy (FANG) announced a $2B share repurchase program [more]
  
• U.S. Steel (X) announced a site selection process for a new $3B mini mill [more]
  
• Facebook (FB) removed a network of accounts in Germany over hate speech and incitement of violence [more]
  
• AMC (AMC) CEO Adam Aron said he expects to accept ethereum ($ETH), bitcoin ($BTC), and litecoin ($LTC) as payment for tickets [more]

2. WALL STREET CALLS: 

• Take-Two (TTWO) downgraded to Market Perform from Outperform at BMO Capital [more]
• Baird upgrades Accolade (ACCD) to Outperform on execution, valuation discount [more]
  
• Jefferies downgrades Las Vegas Sands (LVS) on "growth uncertainty" in Macau [more]
  
• Wynn Resorts (WYNN) downgraded to Hold from Buy at Argus [more]
  
• Piper upgrades Five9 (FIVN) on potential for increased Zoom (ZM) takeover bid [more]
  

3. AROUND THE WEB: 

• Invesco (IVZ) is in talks over a potential merger with State Street's (STT) asset management unit, WSJ reports [more]
• Zymeworks (ZYME) data "could intensify potential sale talks," Dealreporter says [more]
  
• New Jersey will pull investments worth $182M from Unilever (UL) following subsidiary Ben & Jerry's decision to stop selling ice cream in Israeli-occupied territories, NY Times reports [more]
  
• Big box retailers like Best Buy (BBY), Target (TGT), BJ's Wholesale (BJ), and Walmart (WMT) are betting on strong holiday sales, WSJ says [more]
  
• Mitsubishi UFJ (MUFG) is weighing the sale of its U.S. banking arm, Bloomberg reports [more]
  

4. MOVERS: 

• Innate Pharma (IPHA) soars after announcing the results from the COAST Phase 2 trial of monalizumab conducted by AstraZeneca (AZN) [more]
• BeiGene (BGNE) higher after announcing the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted an opinion recommending approval of Brukinsa for the treatment of adult patients with Waldenstrom's macroglobulinemia [more]
  
• Protagonist Therapeutics (PTGX) drops after announcing the FDA has placed a clinical hold on the company’s rusfertide program [more]
  
• TCR2 Therapeutics (TCRR) lower after announcing interim results from its Phase 1/2 trial of gavo-cel [more]
  
• Gritstone bio (GRTS) falls after presenting updated results from the company’s Phase 1/2 GRANITE clinical trial and after announcing the dosing of the first patient in its Phase 2 SLATE clinical trial of [more]
  

5. EARNINGS/GUIDANCE: 

• Manchester United (MANU) reported year-over-year revenue growth in Q4 [more]
• CN (CNI) reaffirmed its 2021 financial outlook targets [more]
  
• IFF (IFF) provided FY21 sales growth guidance [more]
  
• Progressive (PGR) reported earnings and revenue for the month of August [more]
  
• MasterCraft (MCFT) provided Q1 adjusted earnings guidance [more]
  

INDEXES: 

Near midday, the Dow was down 156.52, or 0.45%, to 34,594.80, the Nasdaq was down 137.53, or 0.91%, to 15,044.39, and the S&P 500 was down 29.95, or 0.67%, to 4,443.80.